WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

GeneDx Under Investigation Following Disappointing Q1 2026 Results

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>GeneDx, listed as WGS, is under investigation for possible violations of federal securities laws after reporting a significant operational loss and revising its revenue guidance downward. This news, accompanied by a 50% drop in share price, indicates potential ongoing challenges for the company, leading investors to closely monitor the situation.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>GeneDx faces investigation for potential securities law violations.</li><li>Q1 2026 results show $57.5 million operational loss.</li><li>Company lowers 2026 revenue guidance by $65 million mid-point.</li><li>Substantial goodwill write-down signals strategic challenges ahead.</li><li>Share price plummeted 50% following disappointing financial results.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>GeneDx Holdings Corp. (WGS)</strong>: Under scrutiny for potential securities law violations affecting stock value.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This falls under &#039;Legal&#039; as the ongoing investigation may have significant implications on GeneDx&#039;s operational stability and stock performance, especially given the sharp decline already experienced in its stock price.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Ongoing investigation could lead to further regulatory scrutiny.</li><li>Disappointing financials may impact future investor sentiment significantly.</li><li>Write-down of goodwill raises concerns about company management strategies.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Earnings per share: -$0.28 for Q1 2026.</li><li>Operational loss of $57.5 million reported.</li><li>Revenue guidance cut by approximately $65 million for 2026.</li><li>Write-down of $31.3 million related to goodwill.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>WGS may face downward pressure in the short term due to investigation and lower guidance.</p>
  </section>
</section>


<article>
    <h2>WGS Shareholder Alert: Kirby McInerney LLP Investigates Possible Securities Violations</h2>
    <p>NEW YORK, May 11, 2026 – The law firm <a href="https://www.globenewswire.com/Tracker?data=6mNso8hPWJhXxWr36pK3pR1qcRc8Qy4QSwUp55smzi7mt6LB1Qnk0ISgEuRITALQD5X_a9h5LywI9TZj-tcF7kOerK1X3VZIM0fdnLK1ins=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> has commenced an investigation on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/WGS">WGS</a>) following potential violations of federal securities laws. This inquiry focuses on the Company and its senior management amid concerns regarding unlawful business practices.</p>
    
    <h3>Recent Financial Performance Raises Concerns</h3>
    <p>On May 4, 2026, GeneDx disclosed its financial results for the first quarter of 2026, reporting an earnings per share of **-$0.28** and an operational loss of **$57.5 million**. The Company has also revised its revenue guidance for 2026 downward by approximately **$65 million** at the midpoint. GeneDx cited "lower-than-expected blended average reimbursement rates for exome and genome" and disappointing performance from "noncore business lines," notably Fabric Genomics.</p>
    <p>Additionally, GeneDx has recorded a **$31.3 million** write-down associated with the goodwill and intangible assets of its Fabric Genomics reporting unit. This financial adjustment was attributed to a revision in forecasted cash flows impacted by changes in commercial strategy, go-to-market execution, and diminished revenue and profitability expectations. Following this announcement, GeneDx shares plummeted by **$33.42 per share**, or approximately **50%**, from **$67.93** on May 4, 2026, to close at **$34.51** on May 5, 2026.</p>
    
    <h3>No Lawsuit Filed Yet</h3>
    <p>As of now, no formal lawsuit has been initiated. The investigation by Kirby McInerney LLP is ongoing to determine the potential for claims under federal securities laws. Investors who acquired GeneDx securities and possess relevant information or are seeking further insights into this investigation are encouraged to reach out.</p>
    
    <h3>Contact Information for Investors</h3>
    <p>Interested parties can contact <a href="https://www.globenewswire.com/Tracker?data=oaHa4fI3_wONz41E2Nseh13RNfye4KqGUBK67fVQCxoyPJBGLQpE1d3k48_R_E7A_Ipl0ZqEVbm70HCrKeQaSFuGcC5aJnrj_cDJz6sKd0_pAe3VgU5DIWSyEtd7REve" rel="nofollow" target="_blank">Lauren Molinaro</a> of <a href="https://www.globenewswire.com/Tracker?data=6mNso8hPWJhXxWr36pK3pd5WjRwkd7Tnd0UAMbKPzc0T_qBNf3VCnM8pxS5bLwRtk4HurFtYqBixpFuS7eSdrC_0xBdTY5N_Y1SVsD4tWvw=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> via email at <a href="https://www.globenewswire.com/Tracker?data=-lMSkqWFgELEE60jli6zDyBms7aAHenaAqPefPUuAqscCRHoHOuHQZW_KucG-jBG0QxtMJVEzIC7d9WyOyWR9eCcEUHirN2nFYPE6F1zK0MI3045UdLQUZbJkiZuwSmS" rel="nofollow" target="_blank">investigations@kmllp.com</a> to discuss their rights or interests in this matter, at no cost.</p>
    
    <h3>About Kirby McInerney LLP</h3>
    <p><a href="https://www.globenewswire.com/Tracker?data=6mNso8hPWJhXxWr36pK3pe0PdppiK6jQvt8082S3pgA_m8s2YHMtZ7oMBBQlfaiXpH30DwHl0MWQa_l5d5eJ-yXqCNr63mWJk4yqy-XRCwo=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> is a New York-based plaintiffs’ law firm specializing in securities, antitrust, whistleblower, and consumer litigation. The firm has successfully recovered billions of dollars for shareholders through its securities litigation efforts.</p>

    <p>This notification may constitute Attorney Advertising in certain jurisdictions, according to applicable law and ethical standards.</p>
    
    <h3>Contact Information</h3>
    <p>For inquiries, please reach:</p>
    <ul>
        <li><strong>Kirby McInerney LLP</strong></li>
        <li>Lauren Molinaro, Esq.</li>
        <li>Phone: 212-699-1171</li>
        <li>Website: <a href="https://www.kmllp.com" rel="nofollow" target="_blank">https://www.kmllp.com</a></li>
        <li>Email: <a href="mailto:investigations@kmllp.com">investigations@kmllp.com</a></li>
    </ul>
</article>

GeneDx, listed as WGS, is under investigation for possible violations of federal securities laws after reporting a significant operational loss and revising its revenue guidance downward. This news, accompanied by a 50% drop in share price, indicates potential ongoing challenges for the company, leading investors to closely monitor the situation.

WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News